Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Receives $23.87 Average Price Target from Brokerages

Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) have been assigned a consensus rating of “Hold” from the ten analysts that are presently covering the firm, Marketbeat Ratings reports. Seven research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $24.17.

Several research analysts have recently issued reports on the stock. JPMorgan Chase & Co. upped their price target on shares of Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a “neutral” rating in a report on Wednesday, March 20th. Barclays raised Deciphera Pharmaceuticals from an “underweight” rating to an “equal weight” rating and lifted their target price for the stock from $9.00 to $26.00 in a report on Tuesday. Leerink Partnrs lowered Deciphera Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, April 29th. Guggenheim restated a “neutral” rating on shares of Deciphera Pharmaceuticals in a report on Tuesday. Finally, JMP Securities restated a “market perform” rating on shares of Deciphera Pharmaceuticals in a research report on Tuesday.

Institutional Investors Weigh In On Deciphera Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. raised its position in shares of Deciphera Pharmaceuticals by 96.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,026 shares of the company’s stock worth $26,000 after purchasing an additional 997 shares during the period. Quest Partners LLC bought a new stake in Deciphera Pharmaceuticals during the 4th quarter valued at $30,000. AJOVista LLC bought a new position in shares of Deciphera Pharmaceuticals in the fourth quarter valued at $76,000. Exchange Traded Concepts LLC lifted its stake in shares of Deciphera Pharmaceuticals by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 10,447 shares of the company’s stock valued at $169,000 after buying an additional 2,649 shares in the last quarter. Finally, Aigen Investment Management LP bought a new position in shares of Deciphera Pharmaceuticals in the third quarter valued at $181,000. Institutional investors and hedge funds own 70.96% of the company’s stock.

Deciphera Pharmaceuticals Price Performance

NASDAQ DCPH opened at $25.38 on Monday. The business has a fifty day moving average price of $16.56 and a two-hundred day moving average price of $14.80. Deciphera Pharmaceuticals has a fifty-two week low of $9.90 and a fifty-two week high of $25.47. The stock has a market capitalization of $2.09 billion, a PE ratio of -11.08 and a beta of 0.20.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings results on Tuesday, February 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.58) by $0.04. The company had revenue of $48.30 million during the quarter, compared to the consensus estimate of $45.93 million. Deciphera Pharmaceuticals had a negative net margin of 119.33% and a negative return on equity of 49.44%. The company’s revenue for the quarter was up 32.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.60) earnings per share. As a group, sell-side analysts expect that Deciphera Pharmaceuticals will post -2.16 earnings per share for the current year.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.